A role for PML in innate immunity

Genes and Cancer

Volumn 2, Issue 1, 2011, Pages 10-19

  Lunardi, Andrea ^a   Gaboli, Mirella ^b,c   Giorgio, Marco ^b,d   Rivi, Roberta ^b   Bygrave, Anne ^e,f   Antoniou, Michael ^g,h   Drabek, Dubravka ^e,i   Dzierzak, Elaine ^e,i   Fagioli, Marta ^j   Salmena, Leonardo ^a   Botto, Marina ^k   Cordon Cardo, Carlos ^b,l   Luzzatto, Lucio ^b,m   Pelicci, Pier Giuseppe ^d   Grosveld, Frank ^e,i   Pandolfi, Pier Paolo ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g GUY S HOSPITAL   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF PERUGIA   (Italy)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l NewYork Presbyterian Hospital   (United States)

^m ISTITUTO TOSCANO TUMORI   (Italy)

more..

Author keywords

Botryomycosis; Innate immunity; Pml

Indexed keywords

AMPICILLIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

ABSCESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; ATELECTASIS; BOTRYOMYCOSIS; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENTEROCOCCUS; ESCHERICHIA COLI; EXPERIMENTAL INFECTION; EXTRAMEDULLARY HEMATOPOIESIS; HEPATITIS; IMMUNOGLOBULIN BLOOD LEVEL; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE; LETHALITY; LEUKOCYTOSIS; LISTERIA MONOCYTOGENES; LUNG ALVEOLUS WALL; LUNG EMPHYSEMA; LYMPH NODE HYPERPLASIA; LYSOSOME; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PLASMA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA GENE; PROTEUS MIRABILIS; SALIVARY GLAND; SEPTIC SHOCK; SPLENOMEGALY; STAPHYLOCOCCUS AUREUS; TUMOR SUPPRESSOR GENE;

MUS;

EID: 79960061702     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911402682     Document Type: Article

References (44)

1. Bernardi R, Papa A, Pandolfi PP. Regulation of apoptosis by PML and the PML-NBs. Oncogene. 2008;27:6299-312.
2. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell. 2002;108:165-70.
3. Lin HK, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGF-beta signalling. Nature. 2004;431:205-11.
4. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol. 2007;8:1006-16.
5. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. The mechanisms of PML-nuclear body formation. Mol Cell. 2006;24:331-9.
6. Scaglioni PP, Yung TM, Cai A. CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell. 2006;126:269-83.
7. Trotman LC, Alimonti A, Scaglioni PP, et al. Identification of a tumour suppressor network opposing nuclear Akt function. Nature. 2006;441:523-7.
8. Alcalay M, Tomassoni L, Colombo E, et al. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol. 1998;18:1084-93.
9. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol. 2004;6:665-72.
10. Bernardi R, Guernah I, Jin D, et al. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature. 2006;442:779-85.
11. Trotman LC, Wang X, Alimonti A, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007;128:141-56.
12. Gurrieri C, Capodieci P, Bernardi R, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst. 2004;96:269-79.
13. Regad T, Bellodi C, Nicotera P, Salomoni P. The tumor suppressor Pml regulates cell fate in the developing neocortex. Nat Neurosci. 2009;12:132-40.
14. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008;453:1072-8.
15. Geoffroy MC, Chelbi-Alix MK. Role of promyelocytic leukemia protein in host antiviral defense. J Interferon Cytokine Res. 2011;31:145-58.
16. Gialitakis M, Arampatzi P, Makatounakis T, Papamatheakis J. Gamma interferon-dependent transcriptional memory via relocalization of a gene locus to PML nuclear bodies. Mol Cell Biol. 2010;30:2046-56.
17. Everett RD, Chelbi-Alix MK. PML and PML nuclear bodies: implications in antiviral defence. Biochimie. 2007;89:819-30.
18. Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol. 2005;3:799-808.
19. Carpenter S, O'Neill LA. Recent insights into the structure of Tolllike receptors and post-translational modifications of their associated signalling proteins. Biochem. 2009;J422:1-10.
20. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2009;1:a000141.
21. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124:823-35.
22. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16:91-102.
23. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139:693-706.
24. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285-96.
25. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461-6.
26. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE. Regulation of macrophage function in tumors: the multifaceted role of NFkappaB. Blood. 2009;113:3139-46.
27. Neafie RC, Marty AM. Unusual infections in humans. Clin Microbiol Rev. 1993;6:34-56.
28. Ahdoot D, Rickman LS, Haghighi P, Heard WU. Botryomycosis in the acquired immunodeficiency syndrome. Cutis. 1995;55:149-52.
29. Dinauer MC, Orkin SH. Chronic granulomatous disease. Annu Rev Med. 1992;43:117-24.
30. Pollock JD, Williams DA, Gifford MA. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet. 1995;9:202-9.
31. Rodey GE, Park BH, Ford DK, Gray BH, Good RA. Defective bactericidal activity of peripheral blood leukocytes in lipochrome histiocytosis. Am J Med. 1970;49:322-7.
32. Kaufmann SH, Ladel CH. Role of T cell subsets in immunity against intracellular bacteria: experimental infections of knock-out mice with Listeria monocytogenes and Mycobacterium bovis BCG. Immunobiology. 1994;191:509-19.
33. Adams DO, Hamilton TA. Molecular transductional mechanisms by which IFN gamma and other signals regulate macrophage development. Immunol Rev. 1987;97:5-27.
34. Zucker-Franklin D, Seremetis S, Zheng ZY. Internalization of human immunodeficiency virus type I and other retroviruses by megakaryocytes and platelets. Blood. 1990;75:1920-3.
35. Tanaka T, Akira S, Yoshida K. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell. 1995;80:353-61.
36. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008;18:19-26.
37. Pierce BL, Ballard-Barbash R, Bernstein L. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437-44.
38. Kawano M, Hirano T, Matsuda T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1998;332:83-5.
39. Nagel S, Scherr M, Quentmeier H. HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. Leukemia. 2005;19:841-6.
40. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J. 2007;21:3763-70.
41. Flenghi L, Fagioli M, Tomassoni L, et al. Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. Blood. 1995;85:1871-80.
42. Razani B, Cheng G. NF-kappaB: much learned, much to learn. Sci Signal. 2010;3:pe29.
43. Wang ZG, Delva L, Gaboli M, et al. Role of PML in cell growth and the retinoic acid pathway. Science. 1998;279:1547-51.
44. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol. 1988;141:2407-12.